Skip to main content

Table 1 Patients background

From: The effectiveness of regional cooling for paclitaxel-induced peripheral neuropathy

 

Control group (n = 142)

Cooling group (n = 40)

P-value

Age (min-max)

59.7 ± 11.5 (35–84)

56.5 ± 10.4 (32–77)

0.144

Cancer type

Ovarian (n = 80)

Cervical (n = 14)

Endometrial (n = 48)

Ovarian (n = 23)

Cervical (n = 9)

Endometrial (n = 8)

0.053

Regimen

TC ± BV (n = 137)

TP (n = 2)

TAC or TEC (n = 3)

TC ± BV (n = 35)

TP (n = 5)

0.004

Concomitant platinum

CBDCA (n = 140)

CDDP (n = 2)

CBDCA (n = 35)

CDDP (n = 5)

0.006

Cycle

5.9 ± 0.4

5.9 ± 0.4

0.624

Body-surface area (m2)

1.526 ± 0.151

1.483 ± 0.127

0.233

Initial PTX dose (mg/m2)

170.2 ± 6.9

171.2 ± 8.4

0.944

Cumulative PTX dose (mg/m2)

997.4 ± 78.9

1010.1 ± 95.1

0.483

Cumulative Platinum dose (mg/m2)

CBDCA; 2291.3 ± 391.7

CDDP; 324.8 ± 34.3

CBDCA; 2332.2 ± 301.6

CDDP; 295.7 ± 5.5

0.565

0.311

  1. The value of age, cycle, body-surface area, initial PTX dose, cumulative PTX dose, and cumulative platinum dose were indicated as means ± standard deviation and its p values were calculated by unpaired t-test. The p value of cancer type, regimen, concomitant platinum were calculated by chi-square test. PTX paclitaxel, CBDCA carboplatin, CDDP cisplatin, TC ± BV bevacizumab ± paclitaxel + carboplatin, TP paclitaxel + cisplatin, TAC paclitaxel + doxorubicin + carboplatin, TEC paclitaxel + epirubicin + carboplatin